Table 1 Clinicopathologic characteristics of patient samples in Cohorts 1 and 2
From: Overexpression of MACC1 and Its significance in human Breast Cancer Progression
Characteristic | Cohort 1 | Cohort 2 | ||
|---|---|---|---|---|
| Â | NO. | % | NO. | % |
Total | 245 | 185 | ||
Age | Â | |||
 ≤45 | 95 | 38.8 | 78 | 42.2 |
 >45 | 150 | 61.2 | 107 | 57.8 |
Menopausal status | Â | |||
 Premenopausal | 116 | 53.2 |  |  |
 Postmenopausal | 102 | 46.8 |  |  |
 Unknown | 27 |  |  |  |
Clinical stage | Â | |||
 I | 81 | 33.1 | 21 | 11.4 |
 II | 91 | 37.1 | 80 | 43.2 |
 III | 40 | 16.3 | 59 | 31.9 |
 IV | 33 | 13.5 | 25 | 13.5 |
T classification | Â | |||
 T1 | 110 | 44.9 | 36 | 19.5 |
 T2 | 107 | 43.7 | 92 | 49.7 |
 T3 | 18 | 7.3 | 41 | 22.2 |
 T4 | 10 | 4.1 | 16 | 8.6 |
N classification | Â | |||
 N0 | 135 | 55.1 | 70 | 37.8 |
 N1 | 51 | 20.8 | 78 | 42.2 |
 N2 | 41 | 16.7 | 30 | 16.2 |
 N3 | 18 | 7.3 | 7 | 3.8 |
Distant metastasis | Â | |||
 Yes | 212 | 86.5 | 177 | 95.7 |
 No | 33 | 13.5 | 8 | 4.3 |
Estrogen receptor | Â | |||
 Positive | 174 | 71.0 | 101 | 54.6 |
 Negative | 71 | 29.0 | 84 | 45.4 |
 Unknown | 0 |  | 0 |  |
Progesterone receptor | Â | |||
 Positive | 146 | 66.3 | 110 | 59.5 |
 Negative | 74 | 33.7 | 75 | 40.5 |
 Unkown | 25 |  | 0 |  |
Her2 | Â | |||
 Positive | 43 | 22.3 | 21 | 21.4 |
 Negative | 150 | 77.7 | 77 | 78.6 |
 Unknown | 52 |  | 87 |  |
MACC1 expression | Â | Â | Â | Â |
 High expression | 136 | 55.5 | 111 | 60.0 |
 Low expression | 109 | 44.5 | 74 | 40.0 |
Endocrine therapy | Â | |||
 tamoxifen | 122 | 43.8 |  |  |
 No treatment | 95 | 56.2 |  |  |
 Unknown | 28 |  |  |  |